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Atrial fibrillation (AF) is the most common age-related cardiac arrhythmia. It is a 
progressive disease, which makes treatment difficult. The progression of AF is caused 
by the accumulation of damage in cardiomyocytes, which makes the atria more 
vulnerable for AF. Especially structural remodeling and electrical remodeling, together 
called electropathology, are sustainable in the atria and impair functional recovery to 
sinus rhythm after cardioversion. 
The exact electropathological mechanisms underlying persistence of AF are at present 
unknown. High resolution wavemapping studies in patients with different types of 
AF showed that longitudinal dissociation in conduction and epicardial breakthrough 
were the key elements of the substrate of longstanding persistent AF. A double layer 
of electrically dissociated waves propagating transmurally can explain persistence of 
AF (Double Layer Hypothesis) but the molecular mechanism is unknown. Derailment 
of proteostasis – defined as the homeostasis in protein synthesis, folding, assembly, 
trafficking, guidance by chaperones and clearance by protein degradation systems – 
may play an important role in remodeling of the cardiomyocyte. As current therapies 
are not effective in attenuating AF progression, step-by-step analysis of this process, 
in order to identify potential targets for drug therapy, is essential. In addition, novel 
mapping approaches enabling assessment of the degree of electropathology in the 
individual patient are mandatory to develop patient-tailored therapies. The aims of 
this review are to 1) summarize current knowledge of the electrical and molecular 
mechanisms underlying AF, 2) discuss the shortcomings of present diagnostic 
instruments and therapeutic options and 3) to present potential novel diagnostic tools 
and therapeutic targets.




The first electrocardiogram (ECG) of atrial fibrillation (AF) was recorded by Einthoven in 
1906.1 Nowadays, AF is one of the most common arrhythmias with a prevalence varying 
from <0.1% to >12% in the elderly, which is expected to be doubled in patients over 55 
years by 2060.2,3 AF is originally known as a disease of the aging population. However, 
an increasing prevalence is seen in young adults, especially in endurance athletes4 and 
patients with congenital heart disease.5 Hence, a continuous rise in the number of AF-
associated hospitalizations and healthcare costs is to be expected.6 Several treatment 
modalities have been developed, but all are associated with high recurrence rates or 
negative side effects. The aims of this review are to 1) summarize current knowledge of 
the electrical and molecular mechanisms underlying AF, 2) discuss the shortcomings 
of present diagnostic instruments and therapeutic options and 3) to present potential 
novel diagnostic tools and targets for future therapy.
Deficiencies in Diagnostic Tools of Atrial Fibrillation
AF is usually diagnosed by a surface ECG or Holter recording. However, diagnosis of 
new onset, paroxysmal or asymptomatic AF can be challenging. An ECG only captures 
several seconds of the heart rhythm and episodes of AF can therefore be easily missed. 
The use of long-term ambulatory electrocardiography devices or implantable loop 
recorders increases the chance of detecting AF paroxysms. In addition, these devices 
also allow determination of the total duration of all AF episodes within a specific time 
frame, the so-called AF burden. However, electrocardiographic recordings do not provide 
any information on the mechanism underlying AF. Recent studies7-10 suggest that body 
surface mapping arrays, containing 252 electrodes, may be useful to identify driver 
regions in patients with AF. Yet, none of the currently available recording techniques 
can determine the degree and extensiveness of atrial electropathology. Hence, when 
a patient presents with AF, we have no diagnostic tool available for evaluating the 
mechanism underlying AF and determining the stage of the disease at any time in the 
process.
Mechanisms of Atrial Fibrillation: from past to the present 
Experiments performed by Gordon Moe11 nearly 60 years ago provided the basis for 
the ongoing debate on the underlying cause for AF. In isolated canine atria, he showed 
that AF could be due to either fibrillatory conduction (AF caused by an ectopic focus 
with a high frequency discharge resulting in non-uniform excitation of the atria) or true 
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fibrillation (AF persists independently from the site where it was initiated). In 1959, 
Moe11 introduced the so-called Multiple Wavelet Hypothesis which further described 
the features of true fibrillation. In this hypothesis, Moe postulated that persistence of 
AF depended on the average number of wavelets. With the total number of wavelets 
being increased, the probability of extinguishment and thus termination of AF would 
become smaller. Twenty-six years later, Allessie et al.12 performed the first experimental 
evaluation of Moe’s Multiple Wavelet Hypothesis. In a canine right atrium, during 0.5 
second of acutely induced AF, he demonstrated in series of consecutive excitation 
maps that there was a continuous beat-to-beat change in activation pattern. The 
critical number of wavelets in both right and left atria necessary to perpetuate AF was 
estimated to be between three and six. Ever since, numerous experimental and clinical 
mapping studies,11,13-21 reporting on perpetuation of AF, are supportive on either a focal 
(repetitive ectopic discharges) or re-entrant mechanism (mother-wave, rotor, multiple 
wavelets). In the past years, most clinical studies reported on the presence of rotors in 
patients with various types of AF.20
Electropathology associated with persistence of atrial 
fibrillation
High-resolution wavemapping studies22 of AF in patients with valvular heart disease 
and longlasting persistent AF demonstrated that a large proportion of fibrillation waves 
were so-called focal waves. These waves appeared in the middle of the mapping area 
and could not be explained by fibrillation waves propagating in the epicardial plane. 
Focal fibrillation waves appeared scattered throughout the mapping area and were 
not repetitive (Figure 1). The coupling interval was longer than the dominant AF cycle 
length, and unipolar electrograms at the epicardial origin of these waves exhibited 
R-waves.22 Hence, characteristics of these focal fibrillation waves strongly suggest 
that they originated from endo-epicardial breakthrough. These findings were supported 
by a report from Lee et al.23 who observed that more than one third of the fibrillation 
waves in patients with persistent AF were of ‘focal’ origin without any area sustaining 
focal activity. Based on our observations, we recently introduced a new mechanism 
explaining persistence of AF independently of the presence of foci or re-entrant 
circuits in our Double Layer Hypothesis.22,24 The “Double Layer Hypothesis” states 
that the substrate of longstanding persistent AF in humans is caused by progressive 
endo-epicardial dissociation, transforming the atria into an electrical double layer of 
dissociated waves that constantly ‘feed’ each other (Figure 1). Whereas in patients 
with short-lasting episodes of AF, the endo- and epicardial layers are still activated 
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synchronously, in patients with longstanding persistent AF, the endo- and epicardial 
layers of the atrial wall are activated asynchronously.  Over time, due to electrical and 
structural remodeling of the atria, the atrial wall is gradually transformed into a double 
layer of narrow anatomically delineated pathways. The exact molecular mechanisms 
underlying electrical dissociation are, however, unknown.
Figure 1 Epicardial breakthrough. Upper panel: Beat-to-beat variation in spatiotemporal distribution of 
epicardial breakthrough waves (‘focal waves’) during 6 seconds of  persistent AF in a small area of 1.25 X 
1.25cm between the pulmonary veins. Each asterisk indicates a breakthrough site. The large map shows 
all 55 epicardial breakthroughs sites. The size of the asterisk is proportional to the number of  epicardial 
breakthroughs occurring at that site. The breakthrough map demonstrates a wide distribution of these 
focal waves; none of these breakthrough waves occurred, however, repetitively. Lower panel: schematic 
presentation of excitation of the endo- and epicardial layer explaining how transmural conduction from the 
endocardium to the epicardium gives rise to an epicardial breakthrough wave. Hence, the endocardial layer 
serves in this case as a source for ‘new’ fibrillation waves in the epicardial layer22.
Molecular mechanisms underlying Electropathology AF
As mentioned above, AF is a progressive disease, which can be explained by the fact 
that AF itself induces alterations in both function and structure of the cardiomyocyte. 




During the last decennia, various researchers aimed to identify the molecular 
mechanisms that underlie cardiomyocyte remodeling and AF progression. Although 
several pathways, especially related to ion channel remodeling, have been described, 
the exact molecular mechanisms driving AF remodeling and progression are still 
unidentified. The general concept is that during AF, cardiomyocytes are subjected to 
rapid and irregular excitation causing calcium overload in the cells, which leads to 
fast and reversible electrical remodeling and slower, irreversible structural remodeling 
(Figure 2). The cardiomyocyte responds to a calcium overload by the functional 
downregulation of L-type Ca2+-current channels, which causes the shortening of 
action potential duration (APD) and electrical remodeling, thereby providing a further 
substrate for AF.26-30 Also, several other ion channel currents are affected, either on the 
expression level or phosphorylation and redox status.31-33 In addition, various kinases 
and phosphatases become activated and regulate the function of ion channels and 
other downstream target proteins, for example transcriptions factors, various calcium 
handling proteins (such as RyR2, Sarcoplasmic Reticulum Ca2+-ATPase (SERCA) or 
Na+/Ca2+-exchanger) and the actin cytoskeleton.34-38 
When AF persists beyond a few days, irreversible structural remodeling occurs, 
especially hibernation39 (Figure 2). Various research groups39-41 showed that hibernation 
is a form of tissue adaptation. It is defined as the ability of the cardiomyocytes to 
turn into a non-functional phenotype featuring irreversible degradation of the myofibril 
structure (myolysis), which leads to loss of atrial contraction.
While the early electrical remodeling is reversible30 a ‘second factor’ underlies the 
persistence of AF, having a time course comparable to AF-induced structural changes 
(hibernation/myolysis) in the atrial cardiomyocytes.42 Thus, the prevention of structural 
remodeling represents a key target to attenuate cardiomyocyte remodeling and 
dysfunction and may improve the outcome of (electrical) cardioversion to normal sinus 
rhythm. We have strong indications that derailment of proteostasis represents this 
‘second factor’ that underlies AF progression.38,39,43-46
Derailed proteostasis: novel concept of cardiomyocyte 
remodeling
Proteostasis is defined as the homeostasis in protein synthesis, folding, assembly, 
trafficking, guidance by chaperones and clearance by protein degradation systems.47-50 
Healthy proteostasis is controlled by an exquisitely regulated network of molecular 
components and cellular pathways, the protein quality control (PQC) system.47,51 Cells, 
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including cardiomyocytes, are very sensitive to changes in the intra- and extracellular 
environment, induced by stressors, including AF. Stressors can cause derailment in the 
proteostasis by altering the stability of proteins, leading to protein damage, unfolding 
and breakdown, as observed for cardiac troponins and structural proteins.38,43 In the 
heart, various chaperones, especially Heat Shock Proteins (HSPs), are expressed 
to ensure a healthy cardiomyocyte proteostasis and optimal function of the heart. 
For example, HSP27, cvHSP, HSP20 and HSP22 are important members of the PQC 
system and attenuate derailment of proteostasis in AF by assisting in the refolding of 
unfolded proteins,38,51 prevention of AF-induced damage to contractile proteins44,52 and 
attenuation of protein breakdown.43 In this way, HSPs normalize the proteostasis and 
protect the cardiomyocyte against remodeling and AF progression.
Figure 2 Overview of AF-induced cardiomyocyte remodeling. AF induces time-related progressive 
remodeling. First, AF causes a stressful cellular Ca2+ overload, which results in a direct inhibition of the 
L-type Ca2+-channel, shortening of action potential duration and contractile dysfunction. These changes have 
an early onset and are reversible. The early processes protect the cardiomyocyte against Ca2+ overload but at 
the expense of creating a substrate for persistent AF. When AF persists, derailment of proteostasis occurs, 
which results in microtubule disruption, cytoskeletal changes, and degradation of proteins. The targets 
involved in proteostasis are RhoA/ROCK, HDAC6 and calpain. In addition, HSP induction has been found to 
counteract these targets. Derailment of proteostasis results in structural remodeling, myolysis/hibernation, 
and consequently impaired contractile function and AF persistence. Thus, drugs that normalize proteostasis 
via inhibition of RhoA/ROCK, calpain, and HDAC6, but also via induction of cardioprotective HSPs are of 
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Molecular pathways underlying derailed proteostasis
Recently, several molecular pathways were found to induce derailment of proteostasis. 
These pathways include the persistent activation of calpain, activation of the RhoA/
ROCK pathway and the activation of HDAC6. 
Investigators found proof for a role of persistent activation of the calcium overload-
induced protease calpain to underlie impairment of proteostasis and AF progression 
in experimental cardiomyocyte and Drosophila model systems for AF,43,52,53 but also in 
human permanent AF.39 In experimental studies it was observed that calpain activation 
causes the degradation of contractile and structural proteins, and subsequently 
contributes to structural cardiomyocyte remodeling (myolysis), cardiomyocyte 
dysfunction and AF progression.43,53 The role of calpain was confirmed in human 
AF. Here, a significant induction in calpain activation was observed in patients with 
permanent AF compared to patients with paroxysmal AF and controls in sinus rhythm.39 
Furthermore, patients with permanent AF revealed induced amounts of myolysis, which 
correlated significantly with calpain activity levels, suggesting a role for calpain in 
derailment of cardiomyocyte proteostasis, structural remodeling and AF progression. 
Also, during AF, RhoA-GTPases are activated. RhoA-GTPases represent a family 
of small GTP-binding proteins that are involved in cell cytoskeleton organization, 
migration, transcription and proliferation. They have an important role as regulators 
of the actin cytoskeleton in cardiomyocytes54 and trigger the initiation of AF.55,56 RhoA-
GTPases activation results in conduction disturbances and cardiac dysfunction.57,58 
Recent studies38 revealed that in AF, RhoA-GTPase becomes activated, resulting in the 
activation of its downstream effector ROCK and thereby stimulate the polymerization 
of G-actin to filamentous F-actin stress bundles. These stress bundles impair calcium 
homeostasis and contribute to contractile dysfunction, cardiomyocyte remodeling and 
AF progression.38
Furthermore, it was recently found that histone deacetylases (HDACs), such as HDAC6, 
are implicated in AF-induced cardiomyocyte remodeling.43 HDACs affect cardiomyocyte 
proteostasis by epigenetically regulating protein expression and modulating various 
cytoplasmic proteins, including α-tubulin, a structural protein from the microtubule 
network.59-61 By using mutant constructs, AF-induced contractile dysfunction and 
structural remodeling was proven to be driven by HDAC6 via de-acetylation of α-tubulin 
and finally breakdown of microtubules by calpain. This effect of HDAC6 was observed in 
tachypaced HL-1 atrial cardiomyocytes, Drosophila, dogs and confirmed in patients with 
permanent AF.43 HDAC6 inhibition by tubacin conserved the microtubule homeostasis 
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and prevented depolymerized α-tubulin from calpain-mediated degradation. These 
results indicate a key role for HDAC6 in the derailment of cardiomyocyte proteostasis 
in experimental and clinical AF. 
So, three key pathways in AF-induced structural and functional remodeling have been 
identified, and all these pathways impair a healthy proteostasis of the cardiomyocyte.
Induction of HSPs normalize proteostasis
To maintain a good functioning PQC system, numerous chaperones are expressed to 
ensure a healthy cardiomyocyte proteostasis.38 HSPs are generally under the control 
of heat shock transcription factor 1 (HSF1) and represent important chaperones in 
proteostatic control.47,62 During excessive stress situations, such as AF, HSP levels 
were found to become exhausted.44 This finding suggests that upregulation of HSP 
levels might normalize proteostasis and improve cardiomyocyte function in AF. 
In clinical studies, induced HSP levels are associated with protection against AF 
initiation and progression. HSP70 atrial expression levels were found to correlate with 
reduced incidence of post-operative AF in patients in sinus rhythm undergoing cardiac 
surgery.63,64 In another clinical study,65 a potent Heat Shock Response (HSR) and high 
HSP27 levels have been associated with restoration of normal sinus rhythm in patients 
with permanent AF after mitral valve surgery. Higher atrial HSP27 levels were found to 
be related to shorter AF duration and less myolysis when comparing paroxysmal versus 
persistent AF and sinus rhythm.44,66 These findings suggest that HSPs become activated 
after AF episodes and exhaust in time in a stress-related manner.44 Consequently, 
PQC is lost and incorrect/damaged proteins accumulate in cardiomyocytes, inducing 
or accelerating remodeling, in turn resulting in AF progression and recurrence. Next 
to AF, also a loss of PQC is recognized to contribute to the deterioration of heart 
function, reduction of stress tolerance and the possibility of reducing the threshold for 
manifestation of cardiac disease.67 
Various in vitro and in vivo models for tachypacing-induced AF identified HSPs to protect 
against AF initiation and against the derailment of proteostasis and cardiomyocyte 
remodeling. HSPs increase SERCA activity and stimulate both the reuptake of Ca2+ into 
the sarcoplasmic reticulum and the removal of Ca2+ out of the cardiomyocyte via the 
Na+/Ca2+-exchanger,68 suggesting that HSPs attenuate AF progression by protecting 
against (tachypacing-induced) changes in calcium-handling proteins. Several HSPs 
(including HSP27) were shown to reduce oxidative stress, thereby potentially preventing 




cytoskeleton. This protective effect of HSP27 was found via direct binding to actin 
filaments and indirectly by preserving the redox status.43,44,70-73 Reducing oxidative 
stress preserves proteostasis and electrophysiological and contractile function of 
the cardiomyocyte in AF. Moreover, HSPs prevent calpain activation39,53 and, thereby, 
attenuate contractile protein degradation and contractile dysfunction. 
Deficiencies of Present Therapy of Atrial Fibrillation
Therapy of AF is aimed at either rhythm or rate control. Since AF induces electrical, 
structural and contractile remodeling, therapy aimed at prevention or restoration of 
remodeling and consequently restoration of sinus rhythm should be the strategy of 
first choice.74 The different AF treatment modalities include pharmacological therapy, 
electrical cardioversion (ECV), pacemaker implantation combined with His bundle 
ablation or surgical isolation of the pulmonary veins with or without additional linear 
lesions/substrate modification (endovascular or surgical). According to the Multiple 
Wavelet Theory, the stability of the fibrillatory process is determined by the number of 
simultaneously circulating wavelets. Anti-fibrillatory effects of class IA, IC and III drugs 
are based on widening of the excitable period (difference between AF cycle length and 
refractory period). When the excitable period widens, it is less likely that a fibrillation 
wave encounters atrial tissue, which is still refractory. This in turn decreases the degree 
of fractionation of fibrillation waves and subsequently also the number of fibrillation 
waves. It is most likely that, when patients with AF have a variable degree of remodeling 
due to e.g. dissimilar underlying heart diseases or AF episodes of different durations, 
anti-arrhythmic drugs will also widen the excitable gap to a variable degree. This, in 
turn, may explain differences in inter-individual responses to anti-arrhythmic drugs. 
The acute success rate of intravenous chemical cardioversion (CCV), using various 
drugs including amiodarone and flecainide, is 58-75%75,76 for patients with paroxysmal 
or persistent AF and is highest when performed in AF <48 hours.76 Immediate (prior to 
discharge) AF recurrences were observed in 3% and AF relapsed in 30-40% of patients 
within one year with continuation of anti-arrhythmic drugs.76 When CCV is unsuccessful, 
ECV is next treatment in line. Immediate restoration of sinus rhythm is achieved in 88-
97%.76-78 Comparable to CCV, AF recurrences are common; sinus rhythm is maintained 
for one year in only 40-60% of the patients. 
Circumferential Pulmonary Vein Isolation (PVI), endovascular or surgical, is aimed 
at isolating ectopic foci within the myocardial sleeves of the pulmonary veins. 
Endovascular PVI can be achieved with radiofrequency current, laser or cryothermal 
energy. Navigation of the ablation catheters can be performed either manually guided 
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by fluoroscopy or electro-anatomical mapping systems, or robotically using remote 
(non-) magnetic navigation systems.79-81 Despite the promising acute success rates, 
one year AF free survival is approximately 40-50% and redo ablations are frequently 
performed.79-82 This data is confirmed in a large meta-analysis by Ganesan et al.83 In 
this study, the long-term success rate increased to 79.8%, however, only after multiple 
ablation procedures. The overall complication rate associated with endovascular AF 
ablation is 5%, including phrenic nerve palsy, pulmonary vein stenosis, pericardial 
effusion and cardiac tamponade.82,84 From a theoretical point of view, PVI should be an 
effective treatment modality for patients with paroxysms of AF triggered by ectopic foci 
within the pulmonary veins. Recurrences of AF after pulmonary vein isolation can be 
due to incompleteness of circular lesions, conduction or an arrhythmogenic substrate 
located outside the pulmonary veins.85 In addition, an arrhythmogenic substrate may 
also develop over time as a result of a progressive cardiomyopathy.
Figure 3 Intra-individual variation in electrogram morphology. Typical examples of unipolar fibrillation 
electrograms recorded from the middle of, respectively, the right atrial appendage (RA), Bachmann’s Bundle 
(BB) and the pulmonary vein area (PV), obtained from a patient with mitral valve disease and persistent AF. In 
the right atrium, the fibrillation potentials contain a single deflection whereas fibrillation potentials recorded 
from Bachmann’s Bundle and the pulmonary vein area contain multiple deflections.
Different ablation approaches targeting the assumed substrate of AF have therefore 
been developed in the past years,85 including ablation of ganglionated autonomic 
plexuses in epicardial fat pads or disruption of dominant rotors in the left or right 







(CFAE).86 Wu et al.87 concluded in a meta-analysis that CFAE ablation could reduce 
the recurrence of atrial tachycardia in patients with nonparoxysmal AF after a single 
procedure. This effect was not observed in patients with paroxysmal AF. The reported 
one year AF free survival after the first CFAE ablation is only 29% when performed as a 
standalone procedure86 and 74% in CFAE ablation additional to PVI.86,88 Endovascular 
ablation of the ganglionic plexi as a standalone procedure in patients with paroxysmal 
AF is associated with a significantly lower arrhythmia free survival when compared to 
the PVI.89,90 When performed additionally to (repeat) PVI in patients with persistent AF, 
16 months success rate rises to 59%.90 The recurrence rates of these (concomitant) 
substrate modifications are thus high, indicating that the arrhythmogenic substrate 
underlying persistence of AF was still not fully understood. Our Double Layer 
Hypothesis22,24 provides the explanation why, in case the endo- and epicardial layers 
are electrically dissociated, ablative therapy is not successful anymore.
Figure 4 Inter-individual variation in characteristics of fibrillation waves. Examples of six consecutive 
wavemaps obtained from the right atrial free wall constructed during acute AF (upper panel) and persistent 
AF (lower panel); unipolar fibrillation electrograms recorded in the middle of the mapping area are shown on 
top. The mapping area activated by each individual fibrillation is represented by a color; every color indicates 
the moment of entrance in the mapping area (from red to purple); the arrows indicate the main trajectory of 
the fibrillation wave (black: peripheral fibrillation wave, white epicardial breakthrough wave). During acute AF, 
there are a fewer number of fibrillation waves and the patterns of activation are less complex, compared to 
persistent AF. In addition, ‘focal fibrillation waves’ occur more frequently during persistent AF.
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As large numbers of disorders are associated with AF and patients with AF reveal AF 
episodes of variable duration, it is most likely that there is a large degree of variation 
in the degree of atrial remodeling. In addition to this, within a patient, it is also likely 
that there is intra-atrial variation in the degree of remodeling. Examples of regional 
differences in morphology of unipolar fibrillation potentials are shown in Figure 3. 
Hence, knowledge of the degree and extensiveness of the arrhythmogenic substrate 
in the individual patient is essential in order to evaluate a patient-tailored therapy for 
AF. For this purpose, we developed custom made mapping software (‘wave mapping’) 
which enabled visualization of the individual fibrillation waves and quantification of 
the fibrillatory process. By using this software, we compared electrophysiological 
properties of fibrillation waves recorded during induced AF in patients with normal 
atria (physiological AF), with persistent AF in patients with valvular heart disease 
Figure 5 Atrial epicardial mapping. Activation-, conduction block-, and voltage maps constructed from 
Bachmann’s Bundle, right atrium, crista terminalis, pulmonary vein area, left atrioventricular groove and left 
atrial appendage during sinus rhythm, obtained from a patient with coronary artery disease. Electrograms 
recorded from the middle of the mapping area are shown on top. Arrows in the color-coded activation maps 
show the main trajectory of the excitation wave. Areas of slow conduction (<18cm/s) and conduction block 
(<30cm/s) are represented by respectively blue and red lines. Voltage maps show the peak-to-peak amplitude 
of the atrial potentials.
750	  ms	  
6.1 mV 3.1 % 
5.7 mV 0.8 % 
4.0 mV 3.6 % 
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(pathological AF) and demonstrated that electrical dissociation of atrial muscle 
bundles and epicardial breakthrough of fibrillation waves play a key role in development 
of the substrate of persistent AF (Figure 4).24 In order to diagnose the arrhythmogenic 
substrate of AF in individual patients, we are currently evaluating a real-time, high 
resolution, multi-site epicardial mapping approach of the entire atria (Figure 5) as 
a novel diagnostic tool which can be applied as a routine procedure during cardiac 
surgery. An approach like this allows quantification of electrophysiological properties 
of the entire atria. In such manner, we study electropathology throughout the entire 
atria in patients with and without AF and with a diversity of underlying structural heart 
diseases. This novel mapping approach will not only be used to gain further insights 
into the arrhythmogenic substrate of AF, but will also be used to develop novel therapies 
or to improve existing treatment modalities. For example, it may guide ablative therapy 
when the arrhythmogenic substrate is confined to a circumscribed region. In addition, 
data acquired with this mapping approach will also provide the basis for development 
of less- or non-invasive mapping techniques.
The future: Novel therapeutic targets
Current therapies are directed at suppression of AF symptoms, but are not effective in 
attenuating AF remodeling. Therefore, there is a high need to identify novel therapeutic 
targets which will improve the clinical outcome. Novel targets include RhoA, calpain 
and HDAC6 inhibition, but also HSP induction. Recent studies revealed the important 
role of the RhoA/ROCK pathway activation in structural remodeling of cardiomyocytes 
during AF.38 To maintain proper cardiac function, RhoA/ROCK inhibitors might be of 
therapeutic interest. Several RhoA and ROCK inhibitors have been developed. RhoA 
inhibitors CCG-1423 and Rhosin are studied in the preclinical phase.91,92 Fasudil, 
Ezetimibe and AR-12286 are ROCK inhibitors currently studied in Phase II-IV trials for 
Raynaud’s phenomenon, vascular function study, atherosclerosis and glaucoma (Table 
1).
Calpain activation during AF causes the degradation of contractile and structural 
proteins, resulting in myolysis.38,39,43 In vitro studies showed that inhibitors of calpain 
conserve the cardiomyocyte structure and function and therefore might have beneficial 
effects in the treatment of AF.43,53 Various calpain inhibitors have been developed and 
preclinically studied. Disadvantages of the current developed inhibitors are that they 
show poor selectivity for subtypes of calpain and often have a high LogP value and, 
therefore, are hard to dissolve in aqueous solutions.93 
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HDAC6 inhibition, by tubacin, conserves α-tubulin proteostasis and prevents its 
degradation by calpain, thereby protecting against loss of calcium transient and 
cardiac remodeling in experimental model systems for AF. As tubacin is not suitable 
for in vivo studies due to low drug-likeness,94 other promising HDAC6 inhibitors, such 
as tubastatin A and ACY-1215, have been recently developed (Table 1).94-96 Interestingly, 
tubastatin A showed to protect against tachypacing-induced cardiac remodeling in a 
canine model for AF,52 supporting the use of HDAC6 inhibitors as a novel therapeutic 
approach in AF.
Promoting maintenance of proteostasis by revitalization of the PQC system may 
prevent the derailment of proteostasis and structural and functional remodeling in AF. 
Interestingly, the heat shock response as part of the PQC system can be pharmacologically 
boosted, and, consequently, cardiac remodeling may be prevented, halted or even be 
restored. Indeed, as depicted earlier, increasing HSP expression, by either pharmacologic 
compounds or molecular biological means, displays cardioprotective effects in various 
models for AF and in patients. HSP induction provided protection against loss of actin 
proteostasis by reducing RhoA-GTPase-induced remodeling38 and against activation of 
calpain.38,43,44,46,52,53 Furthermore, in canine models for AF progression, treatment with 
geranylgeranylacetone (GGA) induced HSP expression and prevented AF initiation and 
progression by inhibition of the prolongation of the effective refractory period (ERP), 
shortening of APD and reductions in L-type Ca2+-current and it revealed protective 
effects against atrial conduction abnormalities.44,97
Whether HPS induction also protects via HDAC inhibition is currently unknown. Of all 
HSP inducing compounds, GGA represents the most promosing compound for the 
pharmacological induction of HSPs in AF. GGA has already been applied clinically in 
Japan since 1984 as an anti-ulcer drug with no reported serious adverse reactions.98-102 
Due to high LogP value for GGA, high dosages might be needed, therefore, GGA 
derivatives are developed with improved pharmaco-chemical properties (Table 1).103 
Induction of HSPs is suggested to be the most promising therapeutic approach with 
pleiotropic protective effects.
HSPs as biomarkers 
Following stress, HSPs get expressed intracellular, but can also be presented on the 
cell surface or released to the surroundings.104 HSPs in serum may act as a biomarker 
to reveal the stage of AF. Elevated serum HSP60 levels were found in patients with 
acute myocardial infarction (AMI) and seemed to be predictive for post-AMI adverse 
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Table 1 Novel therapeutic targets 
Drug Target Phase Indication Ref (clinical trials,gov identifier)
GGA HSP 
induction
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(Evelyn et al., 2007)
(Shang et al., 2012)
events.105 Elevated serum HSP70 and HSP60 were found to correlate to the severity 
of metabolic syndrome-associated factors in postmenopausal women.106 HSP60 and 
HSP70 were found to positively associate with severity of cardiovascular disease.107-112 
Patients with coronary artery disease (CAD) have antibodies to HSP27 in serum,113 but 
a correlation between antibody titers to HSP27 and the extent of CAD could not be 
found. Several studies have reported increased serum levels for HSP27 several hours 
after myocardial infarction.114,115 In another study, anti-HSP27 levels were found to be 
higher in patients with more advanced cardiac artery disease, making the authors 
to conclude that serum anti-HSP27 titers may be associated with the presence and 
severity of cardiac artery disease.116 Anti-HSP27 titers measured in patients with stroke 
were found significantly elevated.117 These findings suggest that the measurement of 
HSP levels in serum may be useful as biomarkers of disease initiation and progression. 




AF naturally tends to progress from trigger-dependent paroxysmal AF to a more 
substrate-mediated (longstanding) persistent or permanent AF. Trigger focused 
treatments (endovascular or surgical PVI) might be successful in patients with 
paroxysmal AF, however this approach will not be sufficient for patients suffering 
from more advanced types of AF, who require substrate modification. Even treatments 
aimed at substrate modification, such as CFAE ablation, Cox maze III and ganglion 
ablation, are associated with AF recurrences. This implies insufficient understanding 
of the electrophysiological and structural changes which form a substrate underlying 
AF. Hence, as long as the electropathological substrate remains poorly understood, 
and the stage of electropathology cannot be evaluated, it is challenging to define the 
optimal approach per individual patient. Therefore, research is focused on the dissection 
of molecular mechanisms underlying electropathology. New findings indicate a role 
for derailment of cardiomyocyte proteostasis in AF progression and identified novel 
innovative targets for drug therapy. These targets are directed at the attenuation of 
electropathology and prevention of clinical AF progression. Since various drugs are 
already on in clinical phase II/III for other indications, it seems worthwhile to test some 
in clinical AF.
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